Chinese trial of H1N1 vaccines/NEJM

[Guest guest]

Chinese trial of H1N1 vaccines/NEJM A 2200 subject trial of

Chinese H1N1 vaccines (developed from the same CDC virus as vaccines

developed by western manufacturers) was

published in the NEJM. Four strengths of antigen were used in 4

age groups, with and without an aluminum phosphate (not a novel)

adjuvant.

Of interest: 15 mcg of antigen was sufficient. (This is the

US dose being used.) The aluminum adjuvant did not improve antibody

levels. (No aluminum adjuvant is included in the US vaccine.)

Children under 12 had the lowest antibody titres, but boosted well

following a second dose.

The study only looked at antibody titres, and (like other reported

studies) did not study how protective the vaccine was at preventing cases

of swine influenza.

The placebo really was a placebo (phosphate buffered saline) unlike

most western vaccine trials that use a different vaccine as the control.

With a true placebo, it became apparent that systemic reactions were

3-4 times higher in the vaccine group as compared to the placebo

group. True placebo groups need to be included in US vaccine

trials, for without them the true reaction rates cannot be determined.

Posted by Meryl Nass, M.D. at

11:40 PM 0 comments

--------------------------------------------------------

Sheri Nakken, R.N., MA, Hahnemannian

Homeopath

Vaccination Information & Choice Network, Washington State, USA

Vaccines -

http://www.wellwithin1.com/vaccine.htm

Vaccine Dangers, Childhood Disease Classes & Homeopathy

Online/email courses - next classes start October 28 & 29